UNASSIGNED: The expression of TNF family members and their related lncRNAs in a total of 500 enrolled LUAD patients was collected from The Cancer Genome Atlas (TCGA). Univariate Cox and the least absolute shrinkage and selection operator (LASSO)-Cox analysis was used to construct a TNF family-related lncRNA prognostic signature. Kaplan-Meier (KM) survival analysis was used to evaluate survival status. The time-dependent area under the receiver operating characteristic (ROC) curve (AUC) values were used to assess the predictive value of the signature to 1-, 2-, and 3-year overall survival (OS). Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were applied to identify the signature-related biological pathways. Furthermore, tumor immune dysfunction and exclusion (TIDE) analysis was employed to evaluate immunotherapy response.
UNASSIGNED: A total of 8 TNF-related lncRNAs significantly associated with OS of LUAD patients were used to construct a TNF family-related lncRNA prognostic signature. According to risk score, these patients were divided into high- and low-risk subgroups. The KM survival analysis indicated that patients in the high-risk group showed significantly less favorable OS than that of low-risk group. The AUC values in predicting 1-, 2-, and 3-year OS were 0.740, 0.738, and 0.758, respectively. Moreover, the GO and KEGG pathway analyses demonstrated that these lncRNAs were closely involved in immune-related signaling pathways. The further TIDE analysis indicated that high-risk patients had a lower TIDE score than that of low-risk patients, indicating that high-risk patients may be appropriate candidates for immunotherapy.
UNASSIGNED: For the first time, this study constructed and validated a prognostic predictive signature of LUAD patients based on TNF-related lncRNAs, and the signature showed good performance to predict immunotherapy response. Therefore, this signature may provide new strategies for individualized treatment of LUAD patients.
■从癌症基因组图谱(TCGA)收集总共500名登记的LUAD患者中TNF家族成员及其相关lncRNAs的表达。使用单变量Cox和最小绝对收缩和选择算子(LASSO)-Cox分析来构建TNF家族相关的lncRNA预后特征。Kaplan-Meier(KM)生存分析用于评估生存状态。受试者工作特征(ROC)曲线下的时间依赖性面积(AUC)值用于评估特征对1-,2-,和3年总生存期(OS)。应用基因本体论(GO)功能注释和京都基因和基因组百科全书(KEGG)途径分析来鉴定特征相关的生物学途径。此外,肿瘤免疫功能障碍和排斥(TIDE)分析用于评估免疫治疗反应.
■总共使用8种与LUAD患者OS显著相关的TNF相关lncRNA来构建TNF家族相关lncRNA预后特征。根据风险评分,这些患者分为高危和低危亚组.KM生存分析表明,高风险组患者的OS明显低于低风险组。预测1-的AUC值,2-,3年OS分别为0.740、0.738和0.758。此外,GO和KEGG通路分析表明,这些lncRNAs与免疫相关信号通路密切相关.进一步的TIDE分析表明,高风险患者的TIDE评分低于低风险患者,表明高危患者可能是免疫治疗的合适人选.
■第一次,这项研究基于TNF相关的lncRNAs构建并验证了LUAD患者的预后预测特征,和签名显示良好的性能,以预测免疫治疗反应。因此,这一特征可能为LUAD患者的个体化治疗提供新的策略.